Tamoxifen Treatment and Ovarian Changes in Premenopausal Breast Cancer Patients
Author Information
Author(s): I. Cohen, D.J.D. Rosen, M. Altaras, Y. Beyth, J. Shapira, D. Yigael
Primary Institution: Sapir Medical Center, Kfar Saba, Israel
Hypothesis
Tamoxifen treatment in premenopausal breast cancer patients may lead to ovarian overstimulation and morphological changes.
Conclusion
Tamoxifen treatment in premenopausal breast cancer patients is associated with ovarian cyst formation and fibroid overgrowth.
Supporting Evidence
- Tamoxifen-treated patients had persistent bilateral ovarian simple cysts.
- Oestrogen levels in tamoxifen-treated patients were significantly higher than in non-treated patients.
- Some patients experienced progressive growth of fibroid uteri during treatment.
Takeaway
Women taking tamoxifen for breast cancer might develop cysts in their ovaries and have changes in their uterus, which can cause health problems.
Methodology
The study involved a survey of premenopausal breast cancer patients, comparing those treated with tamoxifen to those who were not, using vaginal ultrasounds and hormonal assessments.
Limitations
The study is based on a small sample size of five tamoxifen-treated patients.
Participant Demographics
All participants were premenopausal breast cancer patients.
Want to read the original?
Access the complete publication on the publisher's website